Grundlæggende statistik
| CIK | 1203957 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to BioNovo, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| January 22, 2013 |
BNVI / BioNovo, Inc. / Empery Asset Management, LP - BIONOVO, INC. Passive Investment SC 13G/A 1 p13-0141sc13ga.htm BIONOVO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bionovo, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 090643206 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| November 1, 2012 |
Bankruptcy or Receivership - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 26, 2012 Date of Report (Date of earliest event reported) Bionovo, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of I |
|
| May 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT TO CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 25, 2012 Date of Report (Date of earliest event reported) Bionovo, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisd |
|
| May 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 25, 2012 Date of Report (Date of earliest event reported) Bionovo, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of Incor |
|
| May 15, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-33498 BIONOVO, INC. (Exact name |
|
| May 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2011 Date of Report (Date of earliest event reported) Bionovo, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorp |
|
| April 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 27, 2012 BIONOVO, INC. |
|
| April 3, 2012 |
Bionovo, Inc. 5858 Horton Street, Suite 400 Emeryville, California 94608 April 3, 2011 BY EDGAR TRANSMISSION AND FEDERAL EXPRESS Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Laura Crotty Re: Bionovo, Inc. Preliminary Proxy Statement on Schedule 14A Filed March 27, 2012 File No. 001-33498 Ladies and Gentlemen: Bionovo, Inc., a Delaware corporation (the “Regi |
|
| April 3, 2012 |
REVISED PRELIMINARY COPY - SUBJECT TO COMPLETION, DATEd april 3, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 3, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-33498 BIONOVO, INC. (Exact name of |
|
| March 27, 2012 |
PRE 14A 1 v307316pre14a.htm FORM PRE 14A PRELIMINARY COPY - SUBJECT TO COMPLETION, DATED MARCH 27, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x |
|
| March 19, 2012 |
BNVI / BioNovo, Inc. / Empery Asset Management, LP - BIONOVO, INC. Passive Investment SC 13G 1 p12-0931sc13g.htm BIONOVO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Bionovo, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 090643206 (CUSIP Number) March 12, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| March 13, 2012 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-167466 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 17, 2010) 14,231,696 shares of Common Stock and Warrants to purchase Common Stock (including up to 11,485,844 shares of Common Stock issuable from time to time upon exercise of such Warrants) On March 12, 2012, Bionovo, Inc. entered into a securities purchase agreement, or the Securities Pu |
|
| March 13, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. |
|
| March 12, 2012 |
Bionovo Restructures Work Force Management Compensation Restructured Exhibit 99.1 Company Contact: David Boyle Tel: 510.601.2000 [email protected] Bionovo Restructures Work Force Management Compensation Restructured EMERYVILLE, Calif. – March 9, 2012 - Bionovo, Inc. (OTC Link Platform: BNVI.PK) today announced that it will need to obtain substantial additional funding to achieve its objectives of internally developing drugs. The Company reduced its workforce by |
|
| March 12, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 9, 2012 BIONOVO, INC. |
|
| March 12, 2012 |
FORM OF WARRANT BIONOVO, INC. Warrant To Purchase Common Stock Exhibit 4.1 FORM OF WARRANT BIONOVO, INC. Warrant To Purchase Common Stock Warrant No.: Number of Shares of Common Stock: Date of Issuance: March [ ], 2012 ("Issuance Date") Bionovo, Inc., a Delaware corporation (the "Company"), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [BUYER], the registered holder hereof or its perm |
|
| March 12, 2012 |
Bionovo Enters Into Agreement for Offering of Common Stock and Warrants Exhibit 99.1 Company Contact: David Boyle Tel: 510.601.2000 [email protected] Bionovo Enters Into Agreement for Offering of Common Stock and Warrants EMERYVILLE, Calif. – March 12, 2012 — Bionovo, Inc. (OTCQB: BNVI) On March 12, 2012, Bionovo, Inc., entered into a securities purchase agreement with investors to purchase an aggregate of 14,231,696 shares of our common stock, par value $0.0001 pe |
|
| March 12, 2012 |
EX-10.1 3 v305518ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT (the "Agreement"), dated as of March 12, 2012, by and among Bionovo, Inc., a Delaware corporation, with headquarters located at 5858 Horton Street, Suite 400, Emeryville, California 94608 (the "Company"), and the investors listed on the Schedule of Buyers attached hereto (individually, |
|
| March 12, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 v3055188k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 12, 2012 BIONOVO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33498 20-5526892 (State or Other Jurisdiction of Incorporation) |
|
| March 1, 2012 |
Bionovo Files Registration Statement for Offering of Convertible Preferred Stock and Warrants Exhibit 99.1 Company Contact: David Boyle Tel: 510.601.2000 [email protected] Bionovo Files Registration Statement for Offering of Convertible Preferred Stock and Warrants EMERYVILLE, Calif. – February 29, 2012 - Bionovo, Inc. (OTC Link Platform: BNVI.PK) has recently filed a registration statement on Form S-1 with the Securities and Exchange Commission (File No. 33-179429) to register the offe |
|
| March 1, 2012 |
Financial Statements and Exhibits, Other Events 8-K 1 v3043738k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2012 BIONOVO, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33498 20-5526892 (State or Other Jurisdiction of Incorpo |
|
| March 1, 2012 |
Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 29, 2012 BIONOVO, INC. |
|
| February 17, 2012 |
STIPULATION FOR SETTLEMENT OF CLAIM IN THE CIRCUIT COURT OF THE 11TH JUDICIAL CIRCUIT, IN AND FOR MIAMI-DADE COUNTY, FLORIDA GENERAL JURISDICTION DIVISION CASE NO. |
|
| February 17, 2012 |
AGREED ORDER GRANTING JOINT EXPEDITED MOTION FOR ORDER APPROVING SETTLEMENT OF CLAIM IN THE CIRCUIT COURT OF THE 11TH JUDICIAL CIRCUIT, IN AND FOR MIAMI-DADE COUNTY, FLORIDA GENERAL JURISDICTION DIVISION CASE NO. |
|
| February 17, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v3030278k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 16, 2012 Date of Report (Date of earliest event reported) Bionovo, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS E |
|
| February 9, 2012 |
As filed with the Securities and Exchange Commission on February 9, 2012 File No. 333-179429 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-5526892 (State or other jurisdiction of incorporation or organizatio |
|
| February 8, 2012 |
Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on February 8, 2012 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-5526892 (State or other jurisdiction of incorporation or organization) (Primary Standard I |
|
| February 7, 2012 |
25 1 v30160825.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 OMB APPROVAL OMB Number 3235-0080 Expires: December 31, 2014 Estimated average burden hours per response . . . 1.00 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33498 Bionovo, Inc. The NASDAQ Capital Mar |
|
| January 27, 2012 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT EX-10.2 3 v300638ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AGREEMENT, entered into as of January 23, 2012 (the “Agreement”), by and between Bionovo, Inc., a Delaware corporation, with its principal office at 5858 Horton Street, Suite 400, Emeryville, CA 94608 (the “Company”), and Mary Tagliaferri (the “Executive”). WITNESSETH: WHEREAS, the Executive is cur |
|
| January 27, 2012 |
8-K 1 v3006388k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 23, 2012 Date of Report (Date of earliest event reported) Bionovo, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (I |
|
| January 27, 2012 |
Bionovo to Voluntarily Delist from NASDAQ Exhibit 99.1 Company Contact: Lisa Walthers Tel: 510 420 4167 [email protected] Bionovo to Voluntarily Delist from NASDAQ EMERYVILLE, Calif. —January 27, 2012 — Bionovo, Inc. (NASDAQ: BNVI), today announced that on January 26, 2012, its Board of Directors decided to seek a voluntary delisting from the NASDAQ Capital Market (“NASDAQ”). On March 14, 2011, the Company received a letter from N |
|
| January 27, 2012 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AGREEMENT, entered into as of January 23, 2012 (the “Agreement”), by and between Bionovo, Inc., a Delaware corporation, with its principal office at 5858 Horton Street, Suite 400, Emeryville, CA 94608 (the “Company”), and Isaac Cohen (the “Executive”). WITNESSETH: WHEREAS, the Executive is currently employed by the Company pursuant to an |
|
| January 10, 2012 |
BNVI / BioNovo, Inc. / Crede CG II, Ltd. Passive Investment SC 13G 1 v245153sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Bionovo, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 090643206 (CUSIP Number) December 30, 2011 (Date of Event which requires filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| January 6, 2012 |
Robert Farrell Joins Bionovo’s Board of Directors Exhibit 99.1 Company Contact Lisa Walthers Tel: 510.420.4167 [email protected] Robert Farrell Joins Bionovo’s Board of Directors EMERYVILLE, Calif., January 5, 2012 — Bionovo Inc. (NASDAQ: BNVI) announced today the appointment of Robert E. Farrell, J.D., to the Company’s Board of Directors. Mr. Farrell will also serve as an independent director and member of the Company’s Audit and Compens |
|
| January 6, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2012 BIONOVO, INC. |
|
| January 4, 2012 |
Bionovo, Inc. Warrant To Purchase Common Stock Exhibit 4.1 Bionovo, Inc. Warrant To Purchase Common Stock Warrant No.: 1 Issuance Date: December 30, 2011 Number of Warrant Shares: 7,608,696 Initial Exercise Price: $0.23 (subject to adjustment as set forth herein) (subject to adjustment as set forth herein) Bionovo, Inc., a Delaware corporation (“Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency |
|
| January 4, 2012 |
Company Contact Lisa Walthers Tel: 510.420.4167 [email protected] Exhibit 99.2 Company Contact Lisa Walthers Tel: 510.420.4167 [email protected] Bionovo Appoints New Senior Vice President and Chief Financial Officer -David Boyle to Join Bionovo- Emeryville, Calif. – January 4, 2012 – Bionovo, Inc. (NASDAQ: BNVI) today announced that David Boyle has joined the Company effective immediately as Senior Vice President and Chief Financial Officer. In that posi |
|
| January 4, 2012 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (“Agreement”) is entered into and effective as of December 30, 2011 (“Effective Date”), by and among Bionovo, Inc., a Delaware corporation (“Company”), and Socius CG II, Ltd., a Bermuda exempted company (including its designees, successors and assigns, “Investor”). RECITALS A. The Company’s board of directors has authori |
|
| January 4, 2012 |
Bionovo Announces $5 Million Financing Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Bionovo Announces $5 Million Financing EMERYVILLE, Calif. – January 3, 2012 — Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that it has entered into a $5 million securities purchase agr |
|
| January 4, 2012 |
$7,500,000 Shares of Common Stock, Associated Warrants, and Associated Additional Investment Rights Filed Pursuant to Rule 424(b)(5) Registration No. 333-167466 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 17, 2010) $7,500,000 Shares of Common Stock, Associated Warrants, and Associated Additional Investment Rights Bionovo, Inc., or the Company, has entered into a securities purchase agreement, or the Securities Purchase Agreement, with Socius CG II, Ltd., a Bermuda exempted company, or Socius |
|
| January 4, 2012 |
[Signature Page to Offer Letter] Exhibit 10.3 January 4, 2012 J. David Boyle II [ADDRESS REDACTED] Re: Offer Letter Dear Mr. Boyle: I am pleased to confirm an offer of employment to you to join BioNovo, Inc. (the “Company”) as its new Senior Vice President and Chief Financial Officer (“CFO”) effective as of January 4, 2012. The terms of your offer are as follows: Annual Salary: Your Annual Salary will be $275,000, payable in acco |
|
| January 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 30, 2011 BIONOVO, INC. |
|
| January 4, 2012 |
Exhibit 3.1 BIONOVO, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A PREFERRED STOCK The undersigned, Tom Chesterman, hereby certifies that: 1. The undersigned is the Chief Financial Officer of Bionovo, Inc., a Delaware corporation (the “Corporation”). 2. The Corporation is authorized to issue 10,000,000 shares of preferred stock. 3. The following resolutions we |
|
| November 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-33498 BIONOVO, INC. (Exact |
|
| November 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2011 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of |
|
| November 10, 2011 |
Bionovo Announces Third Quarter 2011 Highlights and Financial Results Exhibit 99.1 Company Contact: Tom Chesterman Tel: 510.601.2000 [email protected] Bionovo Announces Third Quarter 2011 Highlights and Financial Results EMERYVILLE, Calif. ? November 10, 2011 ? Bionovo, Inc. (NASDAQ: BNVI) today announced third quarter highlights and financial results for the three months ended September 30, 2011. ?We initiated the first pivotal Phase 3 clinical trial and are act |
|
| November 10, 2011 |
CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION BIONOVO INC. (a Delaware corporation) EX-3.4 2 v238665ex3-4.htm EX-3.4 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF BIONOVO INC. (a Delaware corporation) Bionovo, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The certificate of incorporation of the Corporation is hereby amended by insertin |
|
| September 19, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 14, 2011 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of |
|
| September 19, 2011 |
Bionovo Announces An Additional 180 Day Period To Regain Compliance With Nasdaq’s Bid Price Rule Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Bionovo Announces An Additional 180 Day Period To Regain Compliance With Nasdaq?s Bid Price Rule EMERYVILLE, Calif. ? September 19, 2011 - Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced |
|
| August 30, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 30, 2011 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of In |
|
| August 30, 2011 |
Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Bionovo Announces Positive Results of the Tolerability Trial of Menerba (MF101) for Menopausal Hot Flashes Greater Efficacy Observed with Higher Doses EMERYVILLE, Calif. ? August 30, 2011 ? Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatme |
|
| August 8, 2011 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT TO CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 3, 2011 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Juri |
|
| August 8, 2011 |
CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results Exhibit 99.1 Company Contact: Tom Chesterman Tel: 510.601.2000 [email protected] CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results EMERYVILLE, Calif. ? August 5, 2011 - CORRECTED - Bionovo, Inc. (NASDAQ: BNVI) today announced second quarter highlights and financial results for the three months ended June 30, 2011. ?We have made excellent progress on our menopausa |
|
| August 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 3, 2011 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of Inc |
|
| August 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-33498 BIONOVO, INC. (Exact name |
|
| August 3, 2011 |
Bionovo Announces Second Quarter 2011 Highlights and Financial Results Exhibit 99.1 Company Contact: Tom Chesterman Tel: 510.601.2000 [email protected] Bionovo Announces Second Quarter 2011 Highlights and Financial Results EMERYVILLE, Calif. ? August 3, 2011 - Bionovo, Inc. (NASDAQ: BNVI) today announced second quarter highlights and financial results for the three months ended June 30, 2011. ?We have made excellent progress on our menopausal hot flash drug candid |
|
| May 13, 2011 |
d UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 10, 2011 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of Inc |
|
| May 11, 2011 |
Bionovo Announces First Quarter 2011 Highlights and Financial Results Exhibit 99.1 Company Contact: Tom Chesterman Tel: 510.601.2000 [email protected] Bionovo Announces First Quarter 2011 Highlights and Financial Results EMERYVILLE, Calif. ? May 11, 2011 ? Bionovo, Inc. (NASDAQ: BNVI) today announced first quarter highlights and financial results for the three months ended March 31, 2011. ?We started the first quarter by raising the necessary capital to advance M |
|
| May 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 11, 2011 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of Incor |
|
| May 11, 2011 |
LEASE by and between BMR-BRIDGEVIEW TECHNOLOGY PARK LLC, a Delaware limited liability company and BIONOVO, INC. |
|
| May 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 001-33498 BIONOVO, INC. (Exact name |
|
| April 7, 2011 |
SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Bionovo, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 090643206 (CUSIP Number) February 2, 2011 (Date of Event Which Requires Filing of |
|
| April 6, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-33498 BIONOVO, INC. (Exact name of |
|
| March 15, 2011 |
c648148k.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2011 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001 |
|
| February 2, 2011 |
Bionovo Announces Closing of Follow-on Offering of Common Stock and Warrants Exhibit 99.1 Company Contacts: Investor Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces Closing of Follow-on Offering of Common Stock and Warrants EMERYVILLE, Calif. ? February 2, 2011 ? Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and |
|
| February 2, 2011 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 28, 2011 Bionovo, Inc. |
|
| February 2, 2011 |
30,031,200 Shares Warrants to Purchase 15,015,600 Shares BIONOVO, INC. UNDERWRITING AGREEMENT Exhibit 1.1 Execution Copy 30,031,200 Shares Warrants to Purchase 15,015,600 Shares BIONOVO, INC. UNDERWRITING AGREEMENT January 28, 2011 COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Dear Sirs: 1. INTRODUCTORY. Bionovo, Inc., a Delaware corporation (the ?Company?), proposes to sell, pursuant to the terms of this Agreement, to Cowen and Company, LLC, as underwriter (the ?Und |
|
| February 2, 2011 |
BIONOVO, INC. WARRANT TO PURCHASE COMMON SHARES Exhibit 4.1 THE ISSUANCE OF THIS WARRANT AND THE WARRANT SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED BY THE COMPANY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (REGISTRATION NO. 333-171208). THE REGISTERED HOLDER OF THIS WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER O |
|
| January 28, 2011 |
Prospectus Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-171208 Prospectus 30,031,200 Units Units Consisting of One Share of Common Stock and Warrant to Purchase 0.5 Shares of Common Stock We are offering 30,031,200 units, with each unit consisting of one share of our common stock and a warrant to purchase 0.5 shares of our common stock (and the shares of common stock iss |
|
| January 26, 2011 |
SEC Letter January 26, 2011 U.S. Securities and Exchange Commission 100 F. Street, NE Washington, D.C. 20549 Re: Bionovo, Inc. Registration Statement on Form S-1 Filed December 16, 2010 File No. 333-171208 VIA FACSIMILE Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Cowen a |
|
| January 26, 2011 |
Bionovo, Inc. 5858 Horton Street Suite 400 Emeryville, CA 94608 (510) 601-2000 Accleration Request Bionovo, Inc. 5858 Horton Street Suite 400 Emeryville, CA 94608 (510) 601-2000 January 26, 2011 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Bionovo, Inc. Registration Statement on Form S-1 Filed December 16, 2010 File No. 333-171208 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Bionovo, |
|
| January 21, 2011 |
As filed with the Securities and Exchange Commission on January 21, 2011 Table of Contents As filed with the Securities and Exchange Commission on January 21, 2011 File No. |
|
| January 21, 2011 |
BIONOVO, INC. WARRANT TO PURCHASE COMMON SHARES Exhibit 4.11 THE ISSUANCE OF THIS WARRANT AND THE WARRANT SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED BY THE COMPANY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (REGISTRATION NO. 333-171208). BIONOVO, INC. WARRANT TO PURCHASE COMMON SHARES Warrant No.: Number of Common Shares: Date of Issuance: |
|
| January 21, 2011 |
Exhibit 1.1 [FORM OF UNDERWRITING AGREEMENT] 35,000,000 Shares Warrants to Purchase 17,500,000 Shares BIONOVO, INC. UNDERWRITING AGREEMENT January , 2011 COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10022 Dear Sirs: 1. INTRODUCTORY. Bionovo, Inc., a Delaware corporation (the ?Company?), proposes to sell, pursuant to the terms of this Agreement, to Cowen and Company, LLC, as under |
|
| January 21, 2011 |
Letterhead of Greenberg Traurig, LLP SEC Letter Letterhead of Greenberg Traurig, LLP VIA EDGAR January 21, 2011 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Registration Statement on Form S-1/A Ladies and Gentlemen: On behalf of our client Bionovo, Inc. |
|
| January 21, 2011 |
CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION BIONOVO INC. (a Delaware corporation) Exhibit 3.4 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF BIONOVO INC. (a Delaware corporation) Bionovo, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The certificate of incorporation of the Corporation is hereby amended by deleting the first paragraph |
|
| December 16, 2010 |
[Letterhead of Greenberg Traurig, LLP] SEC Cover Letter [Letterhead of Greenberg Traurig, LLP] VIA EDGAR December 16, 2010 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: Registration Statement on Form S-1 Ladies and Gentlemen: On behalf of our client Bionovo, Inc. |
|
| December 16, 2010 |
As filed with the Securities and Exchange Commission on December 16, 2010 Table of Contents As filed with the Securities and Exchange Commission on December 16, 2010 File No. |
|
| December 10, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment 1) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-33498 BIONOV |
|
| November 12, 2010 |
Exhibit 10.3 Master Lease Agreement PHONE: (800) 275-1415 FAX: (800) 743-0177 Full Legal Name Phone Number Bionovo, Inc. (510) 420-4189 Carrying on Business as (If Any) Fax Number Billing Address City State Zip Send Invoice to Attention of: 12635 E. Montview Blvd., Ste 155 Aurora CO 80045 TERMS AND CONDITIONS This MASTER LEASE AGREEMENT (?Agreement?) is dated as of , 20 , and is by and between De |
|
| November 12, 2010 |
Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] FDA Approves Bionovo?s Clinical Development Plan for Menerba Key FDA Clinical Meeting Held; Company on Track to Initiate Phase 3 Trials for Menerba EMERYVILLE, Calif. ? November 10, 2010 ? Bionovo, In |
|
| November 12, 2010 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 11, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) |
|
| November 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 1-33498 BION |
|
| November 12, 2010 |
Exhibit 10.2 SALE AND LEASEBACK AGREEMENT This Sale and Leaseback Agreement (?Agreement?) is dated and effective June 15, 2010 by and between, BIONOVO, INC., 5858 Horton Street, Suite 400, Emeryville, CA 94608 (the ?Seller?) and TFG-COLORADO, L.P., 3165 East Millrock Drive, Suite 400, Salt Lake City, UT 84121 (the ?Buyer?). WHEREAS, Seller requests Buyer to purchase from Seller, in one or more Aut |
|
| November 12, 2010 |
Exhibit 10.1 MASTER LEASE AGREEMENT THIS MASTER LEASE AGREEMENT (?Master Lease?) is made as of June 15, 2010, between TFG-COLORADO, L.P. (?Lessor?), a Utah limited partnership with its chief executive office at 3165 East Millrock Drive, Suite 400, Salt Lake City, Utah 84121, and BIONOVO, INC. (?Lessee?), a Delaware corporation with its chief executive office at 5858 Horton Street, Suite 400, Emery |
|
| November 12, 2010 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 10, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 12, 2010 |
Press Release Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces Third Quarter 2010 Highlights and Financial Results Key FDA Clinical Meeting Held; Company on Track to Initiate Phase 3 Trials for Menerba EMERYVILLE, Calif. – November |
|
| October 7, 2010 |
PROSPECTUS SUPPLEMENT NO. 4 21,395,349 SHARES OF COMMON STOCK BIONOVO, INC. Prospectus Supplement No. 4 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-168197 PROSPECTUS SUPPLEMENT NO. 4 21,395,349 SHARES OF COMMON STOCK BIONOVO, INC. This Prospectus Supplement No. 4 amends our Prospectus dated August 4, 2010. The shares that are the subject of the Prospectus have been registered to permit their sale to the public by the selling stockholder named in |
|
| October 5, 2010 |
2,727,270 Shares Common Stock and Warrants to Purchase up to 2,045,451 Shares Prospectus Supplement Filed Pursuant to Rule 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| October 5, 2010 |
Financial Statements and Exhibits 8-K/A 1 d8ka.htm FORM 8-K AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 1, 2010 Bionovo, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33 |
|
| October 4, 2010 |
Bionovo to Raise $3 Million Through Registered Direct Offering Exhibit 99.1 Company Contacts: Investor Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo to Raise $3 Million Through Registered Direct Offering EMERYVILLE, Calif. ? October 1, 2010 ? Bionovo, Inc. (NASDAQ: BNVI), a drug discovery and development company focused on unmet needs in w |
|
| October 4, 2010 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 1, 2010 Bionovo, Inc. |
|
| October 4, 2010 |
FORM OF SUBSCRIPTION AGREEMENT Exhibit 10.1 FORM OF SUBSCRIPTION AGREEMENT Bionovo, Inc. 5858 Horton Street Suite 400 Emeryville, CA 94608 Gentlemen: The undersigned (the ?Investor?) hereby confirms its agreement with Bionovo, Inc., a Delaware corporation (the ?Company?), as follows: 1. This Subscription Agreement, including the Terms and Conditions For Purchase of Units attached hereto as Annex I (collectively, (this ?Agreemen |
|
| October 4, 2010 |
BIONOVO, INC. WARRANT TO PURCHASE COMMON SHARES Form of Warrant Exhibit 4.1 THE ISSUANCE OF THIS WARRANT AND THE WARRANT SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED BY THE COMPANY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (REGISTRATION NO. 333-167466). BIONOVO, INC. WARRANT TO PURCHASE COMMON SHARES Warrant No.: Number of Common Shares: Da |
|
| October 4, 2010 |
BIONOVO, INC. PLACEMENT AGENCY AGREEMENT October 1, 2010 Exhibit 1.1 BIONOVO, INC. PLACEMENT AGENCY AGREEMENT October 1, 2010 William Blair & Company, L.L.C. 222 West Adams Chicago, IL 60606 Ladies and Gentlemen: Bionovo, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions herein, to issue and sell an aggregate of up to (i) 2,727,270 shares (the “Shares”) of its common stock, $0.0001 par value per share (the “Comm |
|
| September 30, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Amendment No. 1 to Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fr |
|
| September 28, 2010 |
PROSPECTUS SUPPLEMENT NO. 3 21,395,349 SHARES OF COMMON STOCK BIONOVO, INC. Prospectus Supplement No. 3 to the Prospectus dated August 4, 2010 Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-168197 PROSPECTUS SUPPLEMENT NO. 3 21,395,349 SHARES OF COMMON STOCK BIONOVO, INC. This Prospectus Supplement No. 3 amends our Prospectus dated August 4, 2010. The shares that are the subject of the Prospectus have been registered to permit their sale to the publ |
|
| September 27, 2010 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 23, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| September 27, 2010 |
Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] FDA Approves Manufacturing Plan for Menerba, Bionovo?s Menopausal Hot Flash Drug Candidate End of Phase 2, Type B Meeting Provides the Approval of Menerba?s Manufacturing Plan Emeryville, CA, Septembe |
|
| September 16, 2010 |
Correspondence Letter Robert H. Cohen Tel (212) 801-6907 Fax (212) 801-6400 [email protected] September 16, 2010 Via EDGAR United States Securities & Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-7010 Attention: Mr. Jeffrey P. Riedler Re: Bionovo, Inc. Form 10-K for the Fiscal Year Ended December 31, 2009 Filed March 16, 2010 Schedule 14A filed April 2, 2 |
|
| September 8, 2010 |
PROSPECTUS SUPPLEMENT NO. 2 21,395,349 SHARES OF COMMON STOCK BIONOVO, INC. Prospectus Supplement Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. |
|
| August 31, 2010 |
Bionovo Announces Reverse Stock Split Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces Reverse Stock Split Emeryville, CA, August 30, 2010 ? Bionovo, Inc. (NASDAQ: BNVI, BNVID) announced today that it will effect a 1-for-5 reverse stock split, that will become effectiv |
|
| August 31, 2010 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 30, 2010 BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (I |
|
| August 18, 2010 |
Correspondence Letter Robert H. Cohen Tel (212) 801-6907 Fax (212) 801-6400 [email protected] August 18, 2010 Via EDGAR United States Securities & Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549-7010 Attention: Mr. Jeffrey P. Riedler Re: Bionovo, Inc. (the “Company”) Form 10-K for the Fiscal Year Ended December 31, 2009 Filed March 16, 2010 Schedule 14A fil |
|
| August 6, 2010 |
PROSPECTUS SUPPLEMENT NO. 1 21,395,349 SHARES OF COMMON STOCK BIONOVO, INC. Prospectus Supplement No. 1 Filed Pursuant to Rule 424(b)(3) Table of Contents Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-168197 PROSPECTUS SUPPLEMENT NO. 1 21,395,349 SHARES OF COMMON STOCK BIONOVO, INC. This Prospectus Supplement No. 1 amends our Prospectus dated August 4, 2010. The shares that are the subject of the Prospectus have been registered to permit their sale |
|
| August 4, 2010 |
BIONOVO, INC. 21,395,349 Shares Common Stock Prospectus Table of Contents PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. |
|
| August 4, 2010 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 4, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IR |
|
| August 4, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2010 |
Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces Second Quarter 2010 Highlights and Financial Results Key Regulatory Meetings Completed; Company Looks to Initiate Phase 3 Trials for Menerba EMERYVILLE, Calif. ? August 4, 2010 ? Bio |
|
| July 19, 2010 |
As filed with the Securities and Exchange Commission on July 19, 2010 Table of Contents As filed with the Securities and Exchange Commission on July 19, 2010 File No. |
|
| July 19, 2010 |
CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION BIONOVO INC. (a Delaware corporation) EXHIBIT 3.3 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF BIONOVO INC. (a Delaware corporation) Bionovo, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify as follows: 1. The certificate of incorporation of the Corporation is hereby amended by deleting the first paragraph |
|
| July 7, 2010 |
Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces A $15 Million At-The-Market Firm Commitment Financing Agreement Emeryville, CA, July 6, 2010 — Bionovo, Inc. (NASDAQ: BNVI) announced today that it has entered into a common stock pu |
|
| July 7, 2010 |
COMMON STOCK PURCHASE AGREEMENT Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the ?Agreement?), dated as of July 6, 2010 by and between BIONOVO, INC. a Delaware corporation (the ?Company?), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the ?Buyer?). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof. WHEREAS: Subject to the terms |
|
| July 7, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 6, 2010 Bionovo, Inc. |
|
| July 7, 2010 |
Exhibit 4.1 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of July 6, 2010, by and between BIONOVO, INC., a Delaware corporation, (the "Company"), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the ?Buyer?). Capitalized terms used herein and not otherwise defined herein shall have the respective mea |
|
| June 11, 2010 |
As filed with the Securities and Exchange Commission on June 11, 2010 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on June 11, 2010 File No. |
|
| June 11, 2010 |
Form of Indenture between Bionovo, Inc. and one or more trustees to be named Exhibit 4.11 BIONOVO, INC. INDENTURE Dated as of , 20 TABLE OF CONTENTS Page No. Article I DEFINITIONS 1 Section 1.01. Definitions. 2 Article II FORMS OF SECURITIES 9 Section 2.01. Terms of the Securities. 9 Section 2.02. Form of Trustee’s Certificate of Authentication. 9 Article III THE DEBT SECURITIES 10 Section 3.01. A |
|
| May 27, 2010 |
Bionovo, Inc. 5858 Horton Street Suite 400 Emeryville, CA 94608 (510) 601-2000 Bionovo, Inc. 5858 Horton Street Suite 400 Emeryville, CA 94608 (510) 601-2000 May 27, 2010 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Bionovo, Inc. Post-Effective Amendment No. 7 to Form S-1 on Form S-3 Filed May 20, 2010 File No. 333-140607 Ladies and Gentlemen: Pursuant to Rule 461 of the Securities Act of 1933, as amended, Bionovo, Inc., a D |
|
| May 20, 2010 |
Table of Contents File No. 333-140607 As filed with the Securities and Exchange Commission on May 19, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 7 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Exact name of registrant as specified in its charter) Delaware 20-5526892 (State or other juris |
|
| May 20, 2010 |
Jessica Portela Tel 212.801.6921 Fax 212.805.8521 [email protected] May 19, 2010 VIA EDGAR AND FACSIMILE Division of Corporation Finance Securities and Exchange Commission 100 F. Street N.E., Mail Stop 4720 Washington, D.C. 20549 Attention: Mr. Jeffrey P. Riedler Re: Bionovo, Inc. Post-Effective Amendment No. 6 to Form S-1 on Form S-3 Filed May 4, 2010 File No. 333-140607 Dear Mr. Riedler: We are |
|
| May 11, 2010 |
Bionovo Announces First Quarter 2010 Highlights and Financial Results Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces First Quarter 2010 Highlights and Financial Results EMERYVILLE, Calif. ? May 11, 2010 ? Bionovo, Inc. (NASDAQ: BNVI) today announced first quarter highlights and financial results fo |
|
| May 11, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2010 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 11, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IRS |
|
| May 5, 2010 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 3, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IRS E |
|
| May 4, 2010 |
Post-Effective Amendment No. 6 to Form S-1 on Form S-3 Table of Contents File No. 333-140607 As filed with the Securities and Exchange Commission on May 4, 2010 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 6 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Exact name of registrant as specified in |
|
| April 28, 2010 |
Form 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 28, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IR |
|
| April 28, 2010 |
Bionovo to Hold Annual Shareholder Meeting May 3, 2010 Exhibit 99.1 Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo to Hold Annual Shareholder Meeting May 3, 2010 EMERYVILLE, Calif. ? April 28, 2010 ? Bionovo, Inc. (NASDAQ: BNVI) today announced its Annual Meeting of Stockholders will be held on Monday, May |
|
| April 12, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 2, 2010 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2010 |
Correspondence Letter March 31, 2010 VIA EDGAR AND FACSIMILE Division of Corporation Finance Securities and Exchange Commission 100 F. |
|
| March 25, 2010 |
Preliminary Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 19, 2010 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 18, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IRS Employe |
|
| March 19, 2010 |
Bionovo Notified by NASDAQ of Extension Company Provided an Additional 180 Days to Regain Compliance Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Notified by NASDAQ of Extension Company Provided an Additional 180 Days to Regain Compliance Emeryville, Calif. ? March 18, 2010 - Bionovo, Inc. (NASDAQ: BNVI) today announced that on March 16, 2010, the C |
|
| March 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-33498 BIONOVO, IN |
|
| March 15, 2010 |
Bionovo Announces 2009 Highlights and Year-End Financial Results Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces 2009 Highlights and Year-End Financial Results EMERYVILLE, Calif. - March 15, 2010 - Bionovo, Inc. (NASDAQ: BNVI) today announced financial results for the year ended December 31, 2009. ?2009 was |
|
| March 15, 2010 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 15, 2010 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IRS Employe |
|
| November 6, 2009 |
PROSPECTUS SUPPLEMENT NO. 3 26,092,046 SHARES OF COMMON STOCK BIONOVO, INC. Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. |
|
| November 5, 2009 |
EX-99.1 2 v164974ex99-1.htm Company Contacts: Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces Third Quarter 2009 Highlights and Financial Results EMERYVILLE, Calif. – November 5, 2009 — Bionovo, Inc. (NASDAQ: BNVI), a drug discovery and development company focu |
|
| November 5, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 5, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 5, 2009 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IRS Emplo |
|
| October 2, 2009 |
3,230,995 UNITS, EACH CONSISTING OF TEN SHARES OF COMMON STOCK AND TEN WARRANTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Statement No.: 333-161816 PROSPECTUS 3,230,995 UNITS, EACH CONSISTING OF TEN SHARES OF COMMON STOCK AND TEN WARRANTS We are offering 3,230,995 units, each unit consisting of ten shares of our common stock and ten warrants. Each warrant entitles its holder to purchase one share of our common stock at an exercise price of $0.85 per shar |
|
| September 30, 2009 |
DAWSON JAMES SECURITIES, INC. 925 South Federal Highway, Suite No. 600 Boca Raton, Florida 33432 Third Amendment to Letter Agreement Exhibit 10.30 DAWSON JAMES SECURITIES, INC. 925 South Federal Highway, Suite No. 600 Boca Raton, Florida 33432 September 29, 2009 Mr. Tom Chesterman Senior Vice President and Chief Financial Officer Bionovo, Inc. 5858 Horton Street, Suite 400 Emeryville, CA 94608 Re: Amendment of Engagement Letter Dear Mr. Chesterman, This letter amends the letter agreement betw |
|
| September 30, 2009 |
DAWSON JAMES SECURITIES, INC. 925 South Federal Highway, Suite No. 600 Boca Raton, Florida 33432 Exhibit 10.29 DAWSON JAMES SECURITIES, INC. 925 South Federal Highway, Suite No. 600 Boca Raton, Florida 33432 September 28, 2009 Mr. Tom Chesterman Senior Vice President and Chief Financial Officer Bionovo, Inc. 5858 Horton Street, Suite 400 Emeryville, CA 94608 Re: Amendment of Engagement Letter Dear Mr. Chesterman, This letter amends the letter agreement between Bionovo, Inc. and Dawson James S |
|
| September 30, 2009 |
Acceleration Request September 29, 2009 VIA FACSIMILE (202) 772-9217 and EDGAR Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N. |
|
| September 30, 2009 |
As filed with the Securities and Exchange Commission on September 30, 2009 Amendment No. 2 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on September 30, 2009 File No. 333-161816 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Exact name of registrant as specified in its charter) Delaware 6770 20-5526892 (State or |
|
| September 30, 2009 |
DAWSON JAMES SECURITIES, INC. 925 South Federal Highway, Suite No. 600 Boca Raton, Florida 33432 First Amendment to Letter Agreement Exhibit 10.28 DAWSON JAMES SECURITIES, INC. 925 South Federal Highway, Suite No. 600 Boca Raton, Florida 33432 September 23, 2009 Mr. Tom Chesterman Senior Vice President and Chief Financial Officer Bionovo, Inc. 5858 Horton Street, Suite 400 Emeryville, CA 94608 Re: Amendment of Engagement Letter Dear Mr. Chesterman, This letter amends the letter agreement betw |
|
| September 23, 2009 |
September 23, 2009 Via Federal Express and EDGAR Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N. |
|
| September 22, 2009 |
As filed with the Securities and Exchange Commission on September 22, 2009 Amendment No. to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on September 22, 2009 File No. 333-161816 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Exact name of registrant as specified in its charter) Delaware 6770 20-5526892 (State or o |
|
| September 22, 2009 |
Dawson James Securities, Inc. 925 South Federal Highway – Suite #600 Boca Raton, FL 33432 Exhibit 10.27 Dawson James Securities, Inc. 925 South Federal Highway – Suite #600 Boca Raton, FL 33432 September 10, 2009 PERSONAL & CONFIDENTIAL Mr. Tom Chesterman Senior Vice President and Chief Financial Officer Bionovo, Inc. 5858 Horton Street, Suite 400 Emeryville, CA 94608 Dear Tom: Dawson James Securities, Inc. (“DJSI”) is pleased to act as exclusive placement agent for Bionovo, Inc. (the |
|
| September 22, 2009 |
SEC Letter September 22, 2009 VIA US MAIL AND FACSIMILE (202-772-9217) Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N. |
|
| September 21, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 21, 2009 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33498 20-5526892 (State or Other (Commission File Number) (IRS Employer Jurisdiction of |
|
| September 21, 2009 |
EXHIBIT 99.1 Company Contacts: Claire Fong Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency Company Provided 180 Days to Regain Compliance Emeryville, Calif. – September 21, 2009 - Bionovo, Inc. (NASDAQ: BNVI) today annou |
|
| September 21, 2009 |
PROSPECTUS SUPPLEMENT NO. 2 26,092,046 SHARES OF COMMON STOCK BIONOVO, INC. Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. 333-140607 September 21, 2009 PROSPECTUS SUPPLEMENT NO. 2 26,092,046 SHARES OF COMMON STOCK BIONOVO, INC. This prospectus supplement amends the prospectus dated June 26, 2009 to allow certain stockholders or their pledgees, donees, transferees, or other successors in interest (the “Selling Stockholders”), to sell, from time to time, |
|
| September 21, 2009 |
EXHIBIT 99.1 Company Contacts: Claire Fong Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency Company Provided 180 Days to Regain Compliance Emeryville, Calif. – September 21, 2009 - Bionovo, Inc. (NASDAQ: BNVI) today annou |
|
| September 10, 2009 |
Exhibit 4.11 BIONOVO, INC. Form of Warrant for the Purchase of Shares of Common Stock, Par Value $0.0001 per Share No. Issue Date: THIS CERTIFIES that, for consideration, the receipt and sufficiency of which are hereby acknowledged, and other value received, (the ?Holder?) is entitled to subscribe for, and purchase from, BIONOVO, INC., a Delaware corporation (the ?Company?), upon the terms and con |
|
| September 10, 2009 |
As filed with the Securities and Exchange Commission on September 10, 2009 Registration Statement on Form S-1 Table of Contents As filed with the Securities and Exchange Commission on September 10, 2009 File No. |
|
| August 10, 2009 |
Bionovo Announces Second Quarter 2009 Highlights and Financial Results Company Contacts: Claire Fong Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces Second Quarter 2009 Highlights and Financial Results EMERYVILLE, Calif. ? August 10, 2009 - - Bionovo, Inc. (NASDAQ: BNVI) today announced second quarter highlights and financial resu |
|
| August 10, 2009 |
PROSPECTUS SUPPLEMENT NO. 1 26,092,046 SHARES OF COMMON STOCK BIONOVO, INC. Prospectus Supplement Table of Contents Filed Pursuant to Rule 424(b)(3) and Rule 424(c) Registration No. |
|
| August 10, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 10, 2009 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IRS Employ |
|
| June 26, 2009 |
File No. 333-140607 As filed with the Securities and Exchange Commission on June 26, 2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 5 ON FORM S-1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-5526892 (State or other jurisdiction of i |
|
| June 12, 2009 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2009 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33498 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Commis |
|
| June 12, 2009 |
File No. 333-140607 As filed with the Securities and Exchange Commission on June 12, 2009 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 4 ON FORM S-1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Exact name of registrant as specified in its charter) Delaware 2834 20-5526892 (State or other jurisdiction of i |
|
| June 12, 2009 |
Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied Company Contacts: Claire Fong Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied Emeryville, California ? Bionovo Inc. (NASDAQ: BNVI) announced today that an arbitration decision issued on |
|
| May 22, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33498 BIONOVO |
|
| May 7, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 7, 2009 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IRS Employer I |
|
| May 7, 2009 |
Bionovo Announces First Quarter 2009 Highlights and Financial Results Company Contacts: Claire Fong Tom Chesterman Tel: 510.601.2000 [email protected] Investor Contacts: Joe Diaz, Robert Blum Joe Dorame Lytham Partners, LLC Tel: 602.889.9700 [email protected] Bionovo Announces First Quarter 2009 Highlights and Financial Results EMERYVILLE, Calif. ? May 7, 2009 ? Bionovo, Inc. (NASDAQ: BNVI) today announced first quarter highlights and financial results for |
|
| May 7, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission File No. 1-33498 BIONOVO, INC. (Exact name o |
|
| May 1, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 13, 2009 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-33498 BIONOVO, INC. (Exact Name of Re |
|
| March 13, 2009 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.5 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended And Restated Executive Employment Agreement (“Agreement”), originally made by and between Bionovo, Inc. (the “Company”) and Isaac Cohen (“Executive”), effective as of January 1, 2008 (the “Effective Date”), is hereby amended and restated in its entirety effective as of January 1, 2008 to read as follows: Recitals Whereas |
|
| March 13, 2009 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.7 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended And Restated Executive Employment Agreement (“Agreement”), originally made by and between Bionovo, Inc. (the “Company”) and Mary Tagliaferri (“Executive”), effective as of January 1, 2008 (the “Effective Date”), is hereby amended and restated in its entirety effective as of January 1, 2008 to read as follows: Recitals Wh |
|
| March 12, 2009 |
Bionovo Announces 2008 Highlights and Year-End Financial Results Company Contacts: Investor Contacts: Claire Fong Joe Diaz, Robert Blum Tom Chesterman Joe Dorame Tel: 510. |
|
| March 12, 2009 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 12, 2009 Date of Report (Date of earliest event reported) BIONOVO, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) 001-33498 20-5526892 (Commission File Number) (IRS Employe |
|
| December 3, 2008 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2008 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33498 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Com |
|
| December 3, 2008 |
Exhibit 99.1 Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings EMERYVILLE, California, December 3, 2008- Bionovo, Inc. (Nasdaq: BNVI) today announced that the FDA has reviewed the company’s manufacturing and control process descriptions (CMC), and has provided guidance on how Bionovo can move forward with the development of Menerba |
|
| November 4, 2008 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIONOVO, INC. (a Delaware Corporation) May 9, 2007 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIONOVO, INC. (a Delaware Corporation) May 9, 2007 ARTICLE ONE NAME OF CORPORATION The name of the corporation is Bionovo, Inc. (the "Corporation"). ARTICLE TWO PERIOD OF DURATION The period of duration of the Corporation is perpetual or until |
|
| November 4, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33498 BIONOVO, INC. (Exa |
|
| November 4, 2008 |
Exhibit 99.1 BIONOVO ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS Emeryville, CA, November 3, 2008 - Bionovo, Inc. (NASDAQ: BNVI) today announced results for the third quarter of 2008. Quarter Results The company did not report any revenue for the three and nine months ended September 30, 2008. Total operating expenses for the three and nine months ending September 30, 2008 were $5.2 million and |
|
| November 4, 2008 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2008 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33498 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Com |
|
| October 20, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2008 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33498 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Com |
|
| August 28, 2008 |
BIONOVO, INC. 5858 Horton Street, Suite 375 Emeryville, California 94608 BIONOVO, INC. 5858 Horton Street, Suite 375 Emeryville, California 94608 August 28, 2008 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Michael Rosenthall RE: Bionovo, Inc. Registration Statement on Form S-3 (File No. 333-140607) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Bionovo, Inc. (the “Company”) her |
|
| August 6, 2008 |
As Filed with the Securities and Exchange Commission on August 6, 2008 As Filed with the Securities and Exchange Commission on August 6, 2008 Registration No. |
|
| August 6, 2008 |
Robert H. Cohen, Esq. 212-801-6907 [email protected] August 6, 2008 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jeffrey P. Riedler Michael Rosenthall Re: Bionovo, Inc. Registration Statement on Form S-3 Filed July 16, 2008 File No. 333-140607 Gentlemen: On behalf of Bionovo, Inc., a Delaware corporation (t |
|
| August 5, 2008 |
Bionovo, Inc (A Development Stage Company) Condensed Statements of Operations Exhibit 99.1 BIONOVO ANNOUNCES SECOND QUARTER 2008 FINANCIAL RESULTS Emeryville, CA, August 5, 2008 - Bionovo, Inc. (NASDAQ: BNVI) today announced results for the second quarter of 2008. Quarter Results The company did not report any revenue for the three and six months ended June 30, 2008. Revenues were $3,750 and $7,500 for the three and six months ended June 30, 2007, respectively, received fro |
|
| August 5, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2008 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33498 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Commi |
|
| August 5, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33498 BIONOVO, INC. (Exact Na |
|
| July 16, 2008 |
As Filed with the Securities and Exchange Commission on July 16, 2008 As Filed with the Securities and Exchange Commission on July 16, 2008 Registration No. |
|
| July 16, 2008 |
GREENBERG TRAURIG, LLP The MetLife Building 200 Park Avenue New York, New York 10166 July 16, 2008 c54237corresp.htm - Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing GREENBERG TRAURIG, LLP The MetLife Building 200 Park Avenue New York, New York 10166 July 16, 2008 VIA EDGAR TRANSMISSION Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Bionovo, Inc. Registration Statement on Form S-3 for Registration of 62,415,147 Shares of Common Sto |
|
| May 12, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-33498 BIONOVO, INC. (Exact N |
|
| May 9, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2008 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33498 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Commissi |
|
| May 9, 2008 |
Exhibit 99.1 BIONOVO ANNOUNCES FIRST QUARTER 2008 FINANCIAL RESULTS Emeryville, CA, May 9, 2008 - Bionovo, Inc. (NASDAQ: BNVI) today announced results for the first quarter of 2008. Quarter Results The company did not report any revenue for the three months ended March 31, 2008. Revenues for the three months ended March 31, 2007 were $3,750, received from our licensing and technology transfer agre |
|
| April 22, 2008 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 17, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2008 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33498 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Commi |
|
| April 17, 2008 |
John D. Baxter, M.D. Joins Bionovo's Board of Directors Exhibit 99.1 John D. Baxter, M.D. Joins Bionovo's Board of Directors EMERYVILLE, Calif., April 17 ? Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of John D. Baxter, M.D., to the company?s Board of Directors. Dr. Baxter has extensive experience in academic research as well as with pharmaceutical and biotech companies, and in particular in advancing endocrine drugs. ?We are very excit |
|
| April 9, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 4, 2008 Bionovo, Inc. |
|
| April 9, 2008 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 99.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (?Agreement?) is made by and between Bionovo, Inc. (the ?Company?) and Isaac Cohen (?Executive?), effective as of January 1, 2008 (the ?Effective Date?). RECITALS Whereas, Executive is currently employed by the Company as its Chief Executive Officer; Whereas, Executive?s prior |
|
| April 9, 2008 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 99.2 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (?Agreement?) is made by and between Bionovo, Inc. (the ?Company?) and Mary Tagliaferri (?Executive?), effective as of January 1, 2008 (the ?Effective Date?). RECITALS Whereas, Executive is currently employed by the Company as its President, Chief Medical Officer and Chief Regu |
|
| March 17, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2007 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 001-33498 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Co |
|
| March 17, 2008 |
George Butler Joins Bionovo's Board of Directors Exhibit 99.1 George Butler Joins Bionovo's Board of Directors EMERYVILLE, Calif., March 13 /PRNewswire-FirstCall/ - Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of George Butler, Ph.D., to the company's Board of Directors. Dr. Butler has extensive regulatory experience with pharmaceutical and biotech companies, and in particular in advancing cancer drug development and women's heal |
|
| March 17, 2008 |
Louis Drapeau Joins Bionovo's Board of Directors Louis Drapeau Joins Bionovo's Board of Directors EMERYVILLE, Calif., March 14 /PRNewswire-FirstCall/ - Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of Louis Drapeau, to the company's Board of Directors. Mr. Drapeau has extensive financial management experience with emerging pharmaceutical and life science companies. "We are quite excited to have access to Lou's expertise," said Isa |
|
| March 13, 2008 |
e10vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. |
|
| January 15, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-140607 PROSPECTUS SUPPLEMENT NO. 5 Prospectus Supplement No. 5 to Prospectus dated May 25, 2007 as supplemented by Prospectus Supplement No. 1 dated June 4, 2007 Prospectus Supplement No. 2 dated June 5, 2007 Prospectus Supplement No. 3 dated June 18, 2007 Prospectus Supplement No. 4 dated November 21, 2007 BIONOVO, INC. This Prospectus Supplement N |
|
| January 15, 2008 |
Filed Pursuant to Rule 424(b)(3) File Number 333-126399 PROSPECTUS SUPPLEMENT NO. 12 Prospectus Supplement No. 12 to Prospectus dated December 15, 2006 as supplemented by Prospectus Supplement No. 1 dated January 24, 2007 Prospectus Supplement No. 2 dated February 27, 2007 Prospectus Supplement No. 3 dated March 20, 2007 Prospectus Supplement No. 4 dated April 19, 2007 Prospectus Supplement No. 5 |
|
| January 7, 2008 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 31, 2007 Bionovo, Inc. |
|
| January 7, 2008 |
AMENDED AND RESTATED BY-LAWS OF BIONOVO, INC. (a Delaware corporation) (as amended and restated as of December 31, 2007) TABLE OF CONTENTS AMENDED AND RESTATED BY-LAWS OF BIONOVO, INC. (a Delaware corporation) (as amended and restated as of December 31, 2007) PAGE ARTICLE 1 NAME AND OFFICES 1 1.1 Name 1 1.2 Registered Office and Agent 1 1.3 Other Offices 1 ARTICLE 2 DIRECTORS 2 2.1 Management Powe |
|
| November 30, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-126399 PROSPECTUS SUPPLEMENT NO. 11 Prospectus Supplement No. 11 to Prospectus dated December 15, 2006 as supplemented by Prospectus Supplement No. 1 dated January 24, 2007 Prospectus Supplement No. 2 dated February 27, 2007 Prospectus Supplement No. 3 dated March 20, 2007 Prospectus Supplement No. 4 dated April 19, 2007 Prospectus Supplement No. 5 |
|
| November 30, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-140607 PROSPECTUS SUPPLEMENT NO. 4 Prospectus Supplement No. 4 to Prospectus dated May 25, 2007 as supplemented by Prospectus Supplement No. 1 dated June 4, 2007 Prospectus Supplement No. 2 dated June 5, 2007 Prospectus Supplement No. 3 dated June 18, 2007 BIONOVO, INC. This Prospectus Supplement No. 4 supplements our Prospectus dated May 25, 2007 a |
|
| November 30, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (AMENDMENT NO. |
|
| November 29, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 26, 2007 Bionovo, Inc. |
|
| November 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB x Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2007 o Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period to Commission File Number 000-50073 BIONOVO, INC. (Exact name of Small Business Issuer as |
|
| November 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2007 BIONOVO, INC. (Exact name of Registrant as specified in its charter) Delaware 000-50073 20-5526892 (State or other jurisdiction of Incorporation or Organization) (Co |
|
| November 13, 2007 |
BIONOVO ANNOUNCES THIRD QUARTER 2007 FINANCIAL RESULTS Exhibit 99.1 BIONOVO ANNOUNCES THIRD QUARTER 2007 FINANCIAL RESULTS Emeryville, CA ? November 13, 2007 ?Bionovo, Inc (NASDAQ: BNVI) today announced financial results for the third quarter and nine months ended September 30, 2007. Third Quarter Results The company reported revenues for the three months ended September 30, 2007 of $243,375 compared to $3,750 for the same period in 2006. Revenues inc |
|
| November 6, 2007 |
FORM OF COMMON STOCK PURCHASE WARRANT To Purchase __________ Shares of Common Stock of BIONOVO, INC. Exhibit 4.1 FORM OF COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of BIONOVO, INC. THIS COMMON STOCK PURCHASE WARRANT (this ?Warrant?) CERTIFIES that, for value received, (the ?Holder?), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date of issuance of this Warrant set forth below (the |
|
| November 6, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 30, 2007 Bionovo, Inc. |
|
| November 6, 2007 |
Exhibit 99.1 Company Contacts: Investors The Trout Group Ian Clements Tel: 415.392.3385 iclements(?troutgroup.com Media Katherina Audley Tel: 415.847.7295 katherina.audley(?bionovo.com Bionovo Announces Closing of Public Offering of Common Stock Emeryville, CA ? October 31, 2007 ? Bionovo, Inc. (NASDAQ: BNVI), a leader in the discovery and development of safe and effective drugs in the areas of wo |
|
| November 6, 2007 |
Exhibit 1.1 7,000,000 Shares of Common Stock and Warrants to Purchase 3,500,000 Shares of Common Stock BIONOVO, INC. UNDERWRITING AGREEMENT October 31, 2007 BMO Capital Markets Corp. Canaccord Adams Inc. as representatives of the several Underwriters named in Schedule A c/o BMO Capital Markets Corp. 3 Times Square, 29th Floor New York, New York 10036 Ladies and Gentlemen: Bionovo, Inc., a Delaware |
|
| October 30, 2007 |
10,000,000 Shares Common Stock and Warrants to Purchase 5,000,000 Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration File No.: 333-146750 10,000,000 Shares Common Stock and Warrants to Purchase 5,000,000 Shares October 26, 2007 We are offering 10,000,000 shares of our common stock and warrants to purchase 5,000,000 shares of our common stock. A purchaser of common stock in the offering may elect to also purchase a warrant to purchase a share of comm |
|
| October 26, 2007 |
FREE WRITING PROSPECTUS BIONOVO, INC. October 26, 2007 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. |
|
| October 17, 2007 |
As Filed with the Securities and Exchange Commission on October 16, 2007 As Filed with the Securities and Exchange Commission on October 16, 2007 Registration No. |
|
| October 16, 2007 |
Robert H. Cohen 212-801-6907 [email protected] October 15, 2007 VIA EDGAR TRANSMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Sasha S. Parikh Re: Bionovo, Inc. Amendment No. 1 to Form 10-KSB for the Fiscal Year Ended December 31, 2006 Filed March 14, 2007 File No. 000-50073 Ladies and Gentlemen: On behalf of Bionovo, Inc., |
|
| October 16, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB/A Amendment No. 1 x ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2006 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 000-50073 BIONOVO, INC. (Name of Small Business Issuer in I |
|
| September 24, 2007 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration File No.: 333-144035 The information in this preliminary prospectus supplement and accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and are not soliciting an offer to buy these securities in any state where the o |
|
| August 8, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-140607 PROSPECTUS SUPPLEMENT NO. 3 Prospectus Supplement No. 3 to Prospectus dated May 25, 2007 as supplemented by Prospectus Supplement No. 1 dated June 4, 2007 Prospectus Supplement No. 2 dated June 5, 2007 BIONOVO, INC. This Prospectus Supplement No. 3 supplements our Prospectus dated May 25, 2007, as supplemented by Prospectus Supplement No. 1 d |
|
| August 7, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-126399 PROSPECTUS SUPPLEMENT NO. 10 Prospectus Supplement No. 10 to Prospectus dated December 15, 2006 as supplemented by Prospectus Supplement No. 1 dated January 24, 2007 Prospectus Supplement No. 2 dated February 27, 2007 Prospectus Supplement No. 3 dated March 20, 2007 Prospectus Supplement No. 4 dated April 19, 2007 Prospectus Supplement No. 5 |
|
| August 6, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB x Quarterly Report under Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2007 o Transition Report under Section 13 or 15(d) of the Exchange Act For the transition period to Commission File Number 000-50073 BIONOVO, INC. (Exact name of Small Business Issuer as Speci |
|
| July 13, 2007 |
v081009ex99-1 - Converted by SECPublisher 2.1.1.8, created by BCL Technologies Inc., for SEC Filing |
|
| July 13, 2007 |
May 29, 2007 Thomas C. Chesterman [HOME ADDRESS REDACTED] Re: Offer Letter Dear Tom: I am pleased to confirm an offer of employment to you to join BioNovo, Inc. (the "Company") as its new Chief Financial Officer ("CFO") effective as of July 9, 2007. The terms of your offer are as follows: Annual Salary: Your Annual Salary will be $305,000, payable in accordance with the Company's standard payroll |
|
| July 13, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 28, 2007 Bionovo, Inc. |
|
| June 26, 2007 |
As filed with the Securities and Exchange Commission on June 25, 2007 Registration No. |
|
| June 18, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-126399 PROSPECTUS SUPPLEMENT NO. 9 Prospectus Supplement No. 9 to Prospectus dated December 15, 2006 as supplemented by Prospectus Supplement No. 1 dated January 24, 2007 Prospectus Supplement No. 2 dated February 27, 2007 Prospectus Supplement No. 3 dated March 20, 2007 Prospectus Supplement No. 4 dated April 19, 2007 Prospectus Supplement No. 5 da |
|
| June 18, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-140607 PROSPECTUS SUPPLEMENT NO. 3 Prospectus Supplement No. 3 to Prospectus dated May 25, 2007 as supplemented by Prospectus Supplement No. 1 dated June 4, 2007 Prospectus Supplement No. 2 dated June 5, 2007 BIONOVO, INC. This Prospectus Supplement No. 3 supplements our Prospectus dated May 25, 2007 as supplemented by Prospectus Supplement No. 1 da |
|
| June 12, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 12, 2007 Bionovo, Inc. |
|
| June 12, 2007 |
Richard Juelis Joins Bionovo’s Board of Directors Company Contacts: Bionovo, Inc. Jim Stapleton Chief Financial Officer Phone: 510.420.4180 [email protected] Media: Katherina Audley Phone: 415.847.7295 [email protected] Final Version Richard Juelis Joins Bionovo?s Board of Directors Emeryville, CA, June 12, 2007 - Bionovo, Inc. (NASDAQ: BNVI) announced today the appointment of Richard Juelis to the company?s Board of Directors. Mr. Jueli |
|
| June 5, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-126399 PROSPECTUS SUPPLEMENT NO. 8 Prospectus Supplement No. 8 to Prospectus dated December 15, 2006 as supplemented by Prospectus Supplement No. 1 dated January 24, 2007 Prospectus Supplement No. 2 dated February 27, 2007 Prospectus Supplement No. 3 dated March 20, 2007 Prospectus Supplement No. 4 dated April 19, 2007 Prospectus Supplement No. 5 da |
|
| June 5, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-140607 PROSPECTUS SUPPLEMENT NO. 2 Prospectus Supplement No. 2 to Prospectus dated May 25, 2007 as supplemented by Prospectus Supplement No. 1 dated June 4, 2007 BIONOVO, INC. This Prospectus Supplement No. 2 supplements our Prospectus dated May 25, 2007 as supplemented by Prospectus Supplement No. 1 dated June 4, 2007. The shares that are the subje |
|
| June 5, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2007 BIONOVO, INC. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 000-50073 (Commission File Number) 20-5526892 (I. |
|
| June 5, 2007 |
Bionovo’s MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial Company Contacts: Bionovo, Inc. Jim Stapleton Chief Financial Officer Phone: 510.420.4180 [email protected] Media: Katherina Audley Phone: 415.847.7295 [email protected] Bionovo’s MF101 Shows Positive Safety, Tolerability and Efficacy in Phase 2 Trial EMERYVILLE, CA, June 4, 2007— Bionovo, Inc.’s (NASDAQ: BNVI) lead drug candidate, MF101, showed positive Phase 2 results for the treatment |
|
| June 4, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-140607 PROSPECTUS SUPPLEMENT NO. 1 Prospectus Supplement No. 1 to Prospectus dated May 25, 2007 BIONOVO, INC. This Prospectus Supplement No. 1 supplements our Prospectus dated May 25, 2007. The shares that are the subject of the Prospectus have been registered to permit their resale to the public by the selling stockholders named in the Prospectus. |
|
| May 29, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-126399 PROSPECTUS SUPPLEMENT NO. 7 Prospectus Supplement No. 7 to Prospectus dated December 15, 2006 as supplemented by Prospectus Supplement No. 1 dated January 24, 2007 Prospectus Supplement No. 2 dated February 27, 2007 Prospectus Supplement No. 3 dated March 20, 2007 Prospectus Supplement No. 4 dated April 19, 2007 Prospectus Supplement No. 5 da |
|
| May 29, 2007 |
Bionovo Stock to Begin Trading on NASDAQ Capital Market Today Exhibit 99.1 Company Contacts: Bionovo, Inc. Jim Stapleton Chief Financial Officer Phone: 510.420.4180 [email protected] Media: Katherina Audley Phone: 415.847.7295 [email protected] Bionovo Stock to Begin Trading on NASDAQ Capital Market Today Emeryville, CA, May 29, 2007 - Bionovo, Inc. (NASDAQ: BNVI), a drug development company focused on the discovery of novel pharmaceutical agents fo |
|
| May 29, 2007 |
[BIONOVO LOGO] 14,939,820 SHARES Bionovo, Inc. Common Stock Filed Pursuant to 424(b)(3) File No. 333-140607 [BIONOVO LOGO] 14,939,820 SHARES Bionovo, Inc. Common Stock The selling stockholders named in this prospectus are offering an aggregate of up to 14,939,820 shares of our common stock. Of these shares, 4,418,820 are issuable upon the exercise of outstanding warrants. We will not receive any of the proceeds from the sale of shares being sold by the sel |
|
| May 29, 2007 |
Other Events, Financial Statements and Exhibits 8-K 1 v076938.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2007 Bionovo, Inc. (Exact name of registrant as specified in its charter) Delaware 000-50073 20-5526892 (State or other jurisdiction of incorporation or orga |
|
| May 23, 2007 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIONOVO, INC. (Exact name of registrant as specified in its charter) Delaware 22-5526892 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 5858 Horton Street, Suite 375 |
|
| May 11, 2007 |
Filed Pursuant to Rule 424(b)(3) File Number 333-126399 PROSPECTUS SUPPLEMENT NO. 6 Prospectus Supplement No. 6 to Prospectus dated December 15, 2006 as supplemented by Prospectus Supplement No. 1 dated January 24, 2007 Prospectus Supplement No. 2 dated February 27, 2007 Prospectus Supplement No. 3 dated March 20, 2007 Prospectus Supplement No. 4 dated April 19, 2007 and Prospectus Supplement No. |
|
| May 10, 2007 |
CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION BIONOVO, INC. (a Delaware corporation) CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF BIONOVO, INC. (a Delaware corporation) The undersigned, Isaac Cohen, hereby certifies that: 1. He is the Chairman of the Board, President, Chief Executive Officer and Chief Scientific Officer of Bionovo, Inc. (the ?Corporation?), a Delaware corporation, and is duly authorized by the unanimous written consent of the Board of Directors |
|
| May 10, 2007 |
As filed with the U.S. Securities and Exchange Commission on May 10, 2007 As filed with the U.S. Securities and Exchange Commission on May 10, 2007 Registration No. 333-140607 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONOVO, INC. (Name of small business issuer in its charter) Delaware (State or jurisdiction of incorporation or organization) 2834 (Primary Standard |
